These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 29335621)

  • 21. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
    Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapy-related acute myeloid leukemia developing 14 years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H-DNMT3A mutated clone of patient origin.
    Martín I; Navarro B; Villamón E; Solano C; Serrano A; Calabuig M; Amat P; Domingo F; Abellán R; García F; Olivares MD; Chaves FJ; Tormo M; Hernández-Boluda JC
    Exp Mol Pathol; 2018 Aug; 105(1):139-143. PubMed ID: 30017658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome.
    Damiani D; Tiribelli M; Geromin A; Michelutti A; Cavallin M; Sperotto A; Fanin R
    Am J Hematol; 2015 Sep; 90(9):784-9. PubMed ID: 26059733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive value of high EVI1 expression in AML patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation in first CR.
    He X; Wang Q; Cen J; Qiu H; Sun A; Chen S; Wu D
    Bone Marrow Transplant; 2016 Jul; 51(7):921-7. PubMed ID: 27042849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation.
    Ishida H; Kato M; Kudo K; Taga T; Tomizawa D; Miyamura T; Goto H; Inagaki J; Koh K; Terui K; Ogawa A; Kawano Y; Inoue M; Sawada A; Kato K; Atsuta Y; Yamashita T; Adachi S
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2141-2147. PubMed ID: 26271192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.
    Nasilowska-Adamska B; Czyz A; Markiewicz M; Rzepecki P; Piatkowska-Jakubas B; Paluszewska M; Dzierzak-Mietla M; Solarska I; Borg K; Prochorec-Sobieszek M; Szydlo R; Lewandowski K; Skotnicki A; Jedrzejczak WW; Kyrcz-Krzemien S; Komarnicki M; Warzocha K
    Eur J Haematol; 2016 Mar; 96(3):236-44. PubMed ID: 25912052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation.
    Jentzsch M; Grimm J; Bill M; Küpper J; Backhaus D; Brauer D; Schulz J; Franke GN; Vucinic V; Niederwieser D; Platzbecker U; Schwind S
    Bone Marrow Transplant; 2021 Oct; 56(10):2610-2612. PubMed ID: 34267355
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation.
    Grimm J; Bill M; Jentzsch M; Beinicke S; Häntschel J; Goldmann K; Schulz J; Cross M; Franke GN; Behre G; Vucinic V; Pönisch W; Lange T; Niederwieser D; Schwind S
    Bone Marrow Transplant; 2019 Aug; 54(8):1189-1197. PubMed ID: 30504903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.
    El Ghannam D; Taalab MM; Ghazy HF; Eneen AF
    Blood Cells Mol Dis; 2014; 53(1-2):61-6. PubMed ID: 24512939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.
    Decroocq J; Itzykson R; Vigouroux S; Michallet M; Yakoub-Agha I; Huynh A; Beckerich F; Suarez F; Chevallier P; Nguyen-Quoc S; Ledoux MP; Clement L; Hicheri Y; Guillerm G; Cornillon J; Contentin N; Carre M; Maillard N; Mercier M; Mohty M; Beguin Y; Bourhis JH; Charbonnier A; Dauriac C; Bay JO; Blaise D; Deconinck E; Jubert C; Raus N; Peffault de Latour R; Dhedin N
    Am J Hematol; 2018 Mar; 93(3):416-423. PubMed ID: 29226497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia.
    Jethava YS; Sica S; Savani B; Socola F; Jagasia M; Mohty M; Nagler A; Bacigalupo A
    Bone Marrow Transplant; 2017 Nov; 52(11):1504-1511. PubMed ID: 28504666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT.
    Savani BN; Labopin M; Kröger N; Finke J; Ehninger G; Niederwieser D; Schwerdtfeger R; Bunjes D; Glass B; Socié G; Ljungman P; Craddock C; Baron F; Ciceri F; Gorin NC; Esteve J; Schmid C; Giebel S; Mohty M; Nagler A
    Haematologica; 2016 Jun; 101(6):773-80. PubMed ID: 26969081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT.
    Brands-Nijenhuis AV; Labopin M; Schouten HC; Volin L; Socié G; Cornelissen JJ; Huynh A; Ljungman P; Malard F; Esteve J; Nagler A; Mohty M
    Haematologica; 2016 Feb; 101(2):248-55. PubMed ID: 26589909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNMT3A mutations in AML: a new prognostic factor?
    Schwarz J; Marková J
    Leuk Res; 2013 Nov; 37(11):1432-3. PubMed ID: 24045027
    [No Abstract]   [Full Text] [Related]  

  • 35. DNMT3A
    Chen D; Christopher M; Helton NM; Ferguson I; Ley TJ; Spencer DH
    Blood Cancer J; 2018 Apr; 8(4):38. PubMed ID: 29618788
    [No Abstract]   [Full Text] [Related]  

  • 36. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial.
    Fasslrinner F; Schetelig J; Burchert A; Kramer M; Trenschel R; Hegenbart U; Stadler M; Schäfer-Eckart K; Bätzel M; Eich H; Stuschke M; Engenhart-Cabillic R; Krause M; Dreger P; Neubauer A; Ehninger G; Beelen D; Berdel WE; Siepmann T; Stelljes M; Bornhäuser M
    Lancet Haematol; 2018 Apr; 5(4):e161-e169. PubMed ID: 29550384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?
    Paubelle E; Ducastelle-Leprêtre S; Labussière-Wallet H; Nicolini FE; Barraco F; Plesa A; Salles G; Wattel E; Thomas X
    Ann Hematol; 2017 Mar; 96(3):363-371. PubMed ID: 28011984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute myeloid leukaemia in a case with Tatton-Brown-Rahman syndrome: the peculiar
    Hollink IHIM; van den Ouweland AMW; Beverloo HB; Arentsen-Peters STCJM; Zwaan CM; Wagner A
    J Med Genet; 2017 Dec; 54(12):805-808. PubMed ID: 28432085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
    Lekakis L; de Lima M
    Expert Rev Anticancer Ther; 2008 May; 8(5):785-98. PubMed ID: 18471050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of absolute monocyte count post-transplant on the outcome of patients with acute myeloid leukemia undergoing myeloablative allogeneic hematopoietic stem cell transplant with busulfan and cyclophosphamide conditioning.
    Tang L; Wang N; Xing C; Zhuang Q; Liang B; Sun L; Chen Y; Qian Y; Shen Z; Jiang S; Yu K; Feng J
    Leuk Res; 2018 Jun; 69():60-65. PubMed ID: 29660493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.